Looking back, truly amazing that King could bring in $55M in revenue and the manufacturing side of the business was just his side gig. Now the fully dedicated team, and all the business development staff, is now down to $53m.
Interestingly, stumbled across a recent research article on failed PH3 trials. In discussing Peregrine, at the interim lookin the decision became quite simple. To continue and not overtake the placebo/control arm the company would have run out of money.